L-Isoleucinamide, O-(phosphono-κO)-N-(1-oxohexyl)-L-tyrosyl-N-(6-amino-6-oxohexyl)-
- Product Name
- L-Isoleucinamide, O-(phosphono-κO)-N-(1-oxohexyl)-L-tyrosyl-N-(6-amino-6-oxohexyl)-
- CAS No.
- 2093305-05-4
- Chemical Name
- L-Isoleucinamide, O-(phosphono-κO)-N-(1-oxohexyl)-L-tyrosyl-N-(6-amino-6-oxohexyl)-
- Synonyms
- ATH-1017;Fosgonimeton;Fosgonimeton（ATH-1017）;L-Isoleucinamide, O-(phosphono-κO)-N-(1-oxohexyl)-L-tyrosyl-N-(6-amino-6-oxohexyl)-;4-((S)-3-(((2S,3S)-1-((6-Amino-6-oxohexyl)amino)-3-methyl-1-oxopentan-2-yl)amino)-2-hexanamido-3-oxopropyl)phenyl dihydrogen phosphate
- CBNumber
- CB59800204
- Molecular Formula
- C27H45N4O8P
- Formula Weight
- 584.65
- MOL File
- 2093305-05-4.mol
L-Isoleucinamide, O-(phosphono-κO)-N-(1-oxohexyl)-L-tyrosyl-N-(6-amino-6-oxohexyl)- Property
- Density
- 1.212±0.06 g/cm3(Predicted)
- storage temp.
- Store at -20°C, protect from light, stored under nitrogen
- solubility
- DMSO : 125 mg/mL (213.81 mM; Need ultrasonic)
- form
- Solid
- pka
- 1.27±0.30(Predicted)
- color
- White to off-white
Hazard and Precautionary Statements (GHS)
- Symbol(GHS)
-
- Signal word
- Danger
- Hazard statements
-
H302Harmful if swallowed
H311Toxic in contact with skin
H314Causes severe skin burns and eye damage
H411Toxic to aquatic life with long lasting effects
- Precautionary statements
-
P260Do not breathe dust/fume/gas/mist/vapours/spray.
P264Wash hands thoroughly after handling.
P264Wash skin thouroughly after handling.
P270Do not eat, drink or smoke when using this product.
P280Wear protective gloves/protective clothing/eye protection/face protection.
P301+P312IF SWALLOWED: call a POISON CENTER or doctor/physician IF you feel unwell.
P301+P330+P331IF SWALLOWED: Rinse mouth. Do NOT induce vomiting.
P302+P352IF ON SKIN: wash with plenty of soap and water.
P303+P361+P353IF ON SKIN (or hair): Remove/Take off Immediately all contaminated clothing. Rinse SKIN with water/shower.
P304+P340IF INHALED: Remove victim to fresh air and Keep at rest in a position comfortable for breathing.
P305+P351+P338IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continuerinsing.
P310Immediately call a POISON CENTER or doctor/physician.
P312Call a POISON CENTER or doctor/physician if you feel unwell.
P321Specific treatment (see … on this label).
P322Specific measures (see …on this label).
P330Rinse mouth.
P361Remove/Take off immediately all contaminated clothing.
P363Wash contaminated clothing before reuse.
P405Store locked up.
P501Dispose of contents/container to..…
L-Isoleucinamide, O-(phosphono-κO)-N-(1-oxohexyl)-L-tyrosyl-N-(6-amino-6-oxohexyl)- Chemical Properties,Usage,Production
Uses
Fosgonimeton (ATH-1017) is a hepatocyte growth factor receptor (c-Met/HGFR) agonist. Fosgonimeton has neuroprotective effects in both LPS (HY-D1056) -induced neuroinflammation and Aβ-induced AD models[1][2][3][4].
in vivo
Fosgonimeton (0.125-2 mg/kg; Subcutaneous injection; 14 days) improves cognitive dysfunction in rat models of AD induced by Aβ[2].
Fosgonimeton (0.125-1.25 mg/kg; Subcutaneous injection; 14 days) improves cognitive impairment in a LPS (HY-D1056) -induced neuroinflammation model of dementia mice[3].
| Animal Model: | Aβ peptides treated adult male Wistar rats (approximately 210 g)[2] |
| Dosage: | 0.125 mg/kg, 0.25 mg/kg, 0.5 mg/kg, 1 mg/kg and 2 mg/kg |
| Administration: | Subcutaneous injection (s.c.); 14 days |
| Result: | Significantly restored cognitive function at all doses tested. The maximum average degree of recovery was 88% recovery in 0.125 mg/kg treated group. |
| Animal Model: | LPS (HY-D1056) treated CD-1 mice aged four to five weeks old[3] |
| Dosage: | 0.125 mg/kg, 0.25 mg/kg, 0.5 mg/kg and 1.25 mg/kg |
| Administration: | Subcutaneous injection (s.c.); 14 days |
| Result: | Significantly ameliorated cognitive deficits at all doses tested, except for the lowest dose (0.125 mg/kg) tested. |
References
[1] Reda S, et al. Fosgonimeton, a novel, small molecule positive modulator of the HGF/MET system is neuroprotective in primary neuron culture. Alzheimer's Dement. 2022 18: e065874.
[2] Reda SM, et al. Fosgonimeton attenuates amyloid-beta toxicity in preclinical models of Alzheimer's disease. Neurotherapeutics. 2024 Jul;21(4):e00350. DOI:10.1016/j.neurot.2024.e00350
[3] Johnston JL, et al. Fosgonimeton, a Novel Positive Modulator of the HGF/MET System, Promotes Neurotrophic and Procognitive Effects in Models of Dementia. Neurotherapeutics. 2023 Mar;20(2):431-451. DOI:10.1007/s13311-022-01325-5
[4] Leen H. KAWAS, et al. WO2017210489. 2021.
L-Isoleucinamide, O-(phosphono-κO)-N-(1-oxohexyl)-L-tyrosyl-N-(6-amino-6-oxohexyl)- Preparation Products And Raw materials
Raw materials
Preparation Products
L-Isoleucinamide, O-(phosphono-κO)-N-(1-oxohexyl)-L-tyrosyl-N-(6-amino-6-oxohexyl)- Suppliers
- Tel
- tp@aladdinsci.com
- Country
- United States
- ProdList
- 52923
- Advantage
- 58
View Lastest Price from L-Isoleucinamide, O-(phosphono-κO)-N-(1-oxohexyl)-L-tyrosyl-N-(6-amino-6-oxohexyl)- manufacturers
- Product
- Fosgonimeton 2093305-05-4
- Price
- US $0.00-0.00/mg
- Min. Order
- 50mg
- Purity
- 99%
- Supply Ability
- 50g
- Release date
- 2025-04-28